Monoclonal Antibodies (mAbs) to Dominate Protein-Based Therapies Market

With products like Avastin, Remicade, Herceptin and Rituxan having blockbuster status almost each year, the mAbs segment holds a tremendous potential in terms of revenue generation, says RNCOS.

NOIDA, India (prHWY.com) April 18, 2012 - According to our new report, "Global Protein Therapeutics Market Forecast to 2015", the global protein therapeutic market has outpaced growth in the overall pharmaceutical industry in the recent years. Protein therapeutics is already playing a vital role in almost every field of medicine and their usage frequency has also risen significantly. It is expected that the therapeutic proteins market may reach a value of around US$ 112.6 Billion in 2012, an increase of around 7% from the previous year. As protein therapeutics' sector enjoys a much lower threat from generic erosion compared to pharmaceuticals, the future growth seems to be higher for the former.

As per our report, monoclonal antibodies (mAbs) are one of the most promising and fastest growing segments of the protein therapeutics market. The accessibility of human and humanized mAbs has enhanced the success rate in clinical trials for the treatment of cancer and immune-inflammatory diseases like Rheumatoid Arthritis). By the end of 2011, the global mAbs market was estimated to be of worth around US$ 48 Billion and is likely to advance further. One of the main drivers of the mAbs market in future will be the increasing number of cancer cases and immune and inflammatory disorders.

Further our report identifies and analyzes the major emerging trends and illustrates their impact on the performance of protein therapeutics market. It also analyzes all the key market segments by focusing on major companies and products, recent activities, application support in terms of indications, geographical performance, and last but not the least, current and future market size. The report, in such a context, is a prominent source of reliable statistics and information on protein therapeutics.

It is an outcome of an extensive research and in-depth analysis on the market that analyzes the market potential to be generated by protein-based therapies. The forecasts are an aggregate of economic and judgmental analysis on the basis of past trends, challenges, and opportunities for expansion. Major factors that might boost the future market have also been analyzed in a prudent manner. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM389.htm

Some of our Related Reports are:

- Cancer Monoclonal Antibodies Market to 2015 (http://www.rncos.com/Report/IM375.htm)
- Global Biosimilars Market Forecast to 2015 (http://www.rncos.com/Report/IM379.htm)
- US Biotech Market Analysis (http://www.rncos.com/Report/IM0300.htm)
- Global miRNA Market Outlook (http://www.rncos.com/Report/IM286.htm)
- Global HIV Therapeutics Market Analysis (http://www.rncos.com/Report/IM361.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS:

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals study and analyze the industry and its various components, with comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the consultants in meeting their objectives in a cost-effective and timely manner.

###

Tag Words: us epo products

Categories: Health

Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707

Link To This Press Release:

URL HTML Code